Metformin treatment is associated with improved survival in diabetic patients hospitalized with acute heart failure: A prospective observational study using the Korean acute heart failure registry data
Authors' conclusion
Metformin treatment at the time of admission was associated with a lower risk for 1-year mortality in patients with diabetes, hospitalized for acute HF.
Study context
- Population
- Patients with T2D hospitalised for acute heart failure (HF) (Korean Acute Heart Failure registry, 2011–2014) with baseline estimated glomerular filtration rate (eGFR) ≥30 ml/min/1.73 m²; mean age 69 years, 56 % male
- Participants
- 1,309 patients
- Exposure
- Metformin vs no metformin at admission
- Metforminn = 613
- Outcome
- All-cause mortality
- Follow-up
- Within 1 year after discharge
Methodological detailsregistry-based, inverse probability treatment weighting
- Registry-based
- Inverse probability treatment weighting
Main finding
As reported in the abstract
median follow-up 11 months
Metformin vs Non-usersHazard ratio (CI)P value
Unadjusted
0.616(0.464–0.819)
P < 0.001Adjusted
0.677(0.495–0.928)
P = 0.015Observational data: associations, not effects.
Further findings
Mortality by subgroup: baseline kidney function (eGFR <60 or ≥60 ml/min/1.73 m²) and LVEF (<40 %, 40-49 %, ≥50 %)
- Association remains significant irrespective of kidney function
- P for interaction = 0.176
- Association remains significant irrespective of LVEF
- P for interaction = 0.224
Original publication
Metformin treatment is associated with improved survival in diabetic patients hospitalized with acute heart failure: A prospective observational study using the Korean acute heart failure registry data. Diabetes Metab. Published 12 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →